Japan Probes Second Kobayashi Pharma Plant After Consumer Deaths
- By The Financial District

- Apr 2, 2024
- 1 min read
Japanese health authorities are investigating a second Kobayashi Pharmaceutical factory in western Japan following reports of deaths possibly linked to dietary supplements produced by the company, as reported by Tetsushi Kajimoto and Ju-min Park for Reuters.

The investigation, expanding from an initial inspection in Osaka, focuses on the use of "Beni-Koji" red yeast materials in dietary supplements. I Photo: Nedley Health
The investigation, expanding from an initial inspection in Osaka, focuses on the use of "Beni-Koji" red yeast materials in dietary supplements. Kobayashi Pharmaceutical reported five deaths and numerous hospitalizations linked to these supplements, which were marketed to lower cholesterol levels.
The supplements contained Monascus purpureus, a red mold used as a food coloring, and potentially toxic puberulic acid believed to be produced by blue mold Penicillium. The cause of the deaths has not been confirmed, but authorities suspect Beni-Koji may be the culprit, prompting inspections at multiple facilities.





![TFD [LOGO] (10).png](https://static.wixstatic.com/media/bea252_c1775b2fb69c4411abe5f0d27e15b130~mv2.png/v1/crop/x_150,y_143,w_1221,h_1193/fill/w_179,h_176,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/TFD%20%5BLOGO%5D%20(10).png)









